AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

INTRODUCTION There are currently more than 1000 prescription medications available for use in the United States and more than 100,000 over‐the‐counter herbal and dietary supplements (HDS) available for purchase in retail stores and online. In addition, the average adult American receives more than six prescription medications per year.1,2 Many of these drugs and HDS products have been implicated as causes of DILI. Furthermore, DILI is a leading reason for regulatory actions regarding drugs in development as well as those in the marketplace.1 Confidently establishing a diagnosis of DILI is difficult because of the need to exclude more common competing causes of liver injury, the protean clinical manifestations from an individual agent, and the lack of a validated diagnostic biomarker.3–5 This guidance was developed with the support and oversight of the American Association for the Study of Liver Diseases Practice Guidelines Committee, who chose to commission a guidance, rather than a guideline, because of the paucity of randomized controlled trials on this topic. This document was developed by consensus of an expert panel and provides guidance statements based on formal review and analysis of the literature on the topics and questions related to the needs of patients with drug and supplement–induced liver injury. The aim of this practice guidance is to provide recommendations regarding the common clinical, laboratory, and histological features seen in patients with DILI based on observational and epidemiological data reported in case series or DILI registries. In addition, expert opinion–based recommendations for patient management, including risk stratification, are provided to assist patients and practitioners. DILI classification DILI can be mechanistically classified as being either direct (i.e., dose‐dependent, intrinsic, and predictable) or idiosyncratic (largely dose‐independent, idiosyncratic, and unpredictable) (Table 1). Direct hepatotoxins such as acetaminophen (APAP) (N‐acetyl‐para‐aminophenol) can cause liver injury in nearly all exposed individuals if a threshold dose or duration is exceeded. In contrast, idiosyncratic hepatotoxins are usually neither dose‐related nor rather or drug DILI is with drugs in in 1000 to in a exposed patients have or features is implicated in of idiosyncratic classification of DILI classification Direct in usually to of injury or or of injury is or on liver or from of is the of the drug the leading to a of liver injury. idiosyncratic hepatotoxins are of the dose of and have a of to with clinical of the with and of statements be with the of patients with DILI. Direct hepatotoxins such as can cause liver injury in nearly all exposed individuals a threshold dose or duration of use is exceeded. DILI is of the dose and duration of use and by a and drug and clinical and histological DILI is to from an to the drug hepatotoxins are of the dose and have a and manifestations from the of the drug on the liver or of idiosyncratic DILI DILI is with an in the of to per 100,000 or per in the The of idiosyncratic DILI based on the case as well as the for case the to be in per 100,000 adult patients who of the implicated drugs in the United States and per 100,000 patients a The of idiosyncratic DILI is in being reported as as of DILI the of drugs and of patients and in case as well as in and and in the (Table and with DILI in United Study case case and Liver implicated drug drugs drugs or or implicated The duration of are as or Liver herbal and dietary case based on the cause of in individual to DILI and The the in the individual for the to based on the causes of idiosyncratic DILI of medications can cause idiosyncratic drug are more implicated than and are more implicated than the implicated HDS products in and for of DILI In contrast, HDS products a of in the United and with an is the implicated individual in in (Table risk of idiosyncratic DILI is by and idiosyncratic DILI is of the dose or duration of implicated drugs are a dose of per than of DILI in liver in the United States by medications with In dose the risk of idiosyncratic DILI as seen with dose or the with and in the liver are with an in with a dose In addition, drugs and in in are with DILI risk in of drugs been with an risk of DILI in and and The of and and on DILI is well because of the lack of epidemiological to DILI with DILI with patient this be in by use with with more and the DILI was more than in than than In addition, to be risk of and individuals are more to DILI from and case series an of with and to be with and Liver is the common drug is the leading cause in In addition, more to have and In contrast, more to a or liver than the of the of are to these and been with an risk of and have been with in the of was with clinical in patients in the Furthermore, are data the of and on DILI The by liver DILI DILI by been with a with the of liver than risk related to and have been reported as DILI (Table in been with to be a risk for DILI and with an of have as risk for drugs or HDS In the have because of the of DILI in the a in to be in DILI diagnosis and with DILI in or and as in the the the provided be for for of and DILI Liver to the of the based on the reported of statements The of idiosyncratic DILI in the is in data and are the implicated in the DILI series HDS are implicated in and are implicated in as The dose of a and of the risk of DILI data to and and as risk for DILI drugs are more to cause DILI in individuals are more implicated in such as and are with and of DILI with the of and in DILI is with liver are risk of liver injury with drugs In addition, with liver are risk of with a DILI in is a risk drugs and have been with to individual the clinical of in DILI diagnosis to be to DILI DILI is a clinical diagnosis of on a including the and of liver and drug and of causes of liver The for DILI and and direct and are a of 1). DILI is as of the or of or if is on with or or with or DILI with of to of individuals in the have liver because of and common diagnostic for patients with DILI. diagnosis of DILI on of clinical and drug with of more common causes of liver injury. herbal and dietary of including the use of HDS is in all DILI This and of the dose and use of the data (i.e., clinical drug and (i.e., to DILI of a drugs have In contrast, can have of DILI is to to an agent, is to to an agent, such as cause DILI. of medications to the or if cause DILI because of the dose of clinical of liver injury been reported for a or HDS can be in an is the cause of the injury. The of liver injury the for competing causes of liver 1). In the of injury can be as with a of with a of or can be more and the as by of liver injury, an of liver injury, and an and a liver injury The is the of the of injury can as the a drug be with more than clinical causes of liver injury for is for all patients with DILI including and to exclude 1). In of in the analysis of the for of DILI is is reported in developed because of to was in in the are regarding of the available for be in including a or in with in patients with DILI for with for and and are drugs can an with or are risk for liver injury, usually by and a in by with or In can be In for is to for In patients with a of than be if are and with and Furthermore, for in this is patients with DILI of liver with an to for of or liver such as or be to for or drugs have been with clinical and such as or are in DILI can with a of clinical and histological from the on and of and histological of idiosyncratic DILI of drugs with or and or the with and or in or with either or by to or with or than with with the of in with or or injury and in with more and injury injury with and liver in the or with to the and and of and of and in a of with in of of and by a either and or and DILI of to with of the or to for common are and and of liver injury drug is in DILI of injury the to the is a of the drug with reported in such as The provides a of the clinical features of idiosyncratic DILI to more than 1000 prescription drugs and HDS are from the In addition, provides a of have been to a as or more of liver and statements DILI is as of the or or if is on with or or with or drugs cause liver injury the of use have or drug of a patient with DILI a and HDS the DILI be by the and can the of causes of liver injury. causes of liver injury is in all DILI including for liver and drugs have been with and be in the for a of the literature on liver injury to 1000 prescription drugs and more than Liver in DILI a liver is to can be in causes of liver and in the in a diagnosis of DILI in of clinical medications are with histological of liver injury can be on can be the liver or with drug or the patient and can be to the of liver a liver causes of or can the clinical or to liver The in the of a liver for a patient with DILI is to the of injury, as are histological of to of DILI with liver injury and of or with or This histological of and or (Table diagnostic to from features in such as of an the of and are DILI and in DILI and are for more and be by a and the be by The of in from DILI to as have been The histological in DILI is injury, with and with on liver is and the of with being in than is an of and liver are in DILI because of and a of those with of DILI DILI and In the be the histological and as in and the is the of by more In the and have injury or to the is common histological manifestations of DILI liver and be is related to injury, and or usually to on nor with and liver can DILI in injury to the development of and as and as either or as and development is with and histological features and be seen on a liver in a patient with DILI. of and of as are in the of or of and is of DILI seen as with to an to drugs and the of DILI and liver can provide The of and of are with the of and is with in a of DILI case to DILI is the of liver from DILI of the of liver injury, the DILI as the In contrast, a liver liver is or on statements Liver is to a diagnosis of idiosyncratic DILI be in DILI with a or and in those with diagnostic a is usually in or liver can the drugs based on histological and can exclude liver of histological been reported in patients with and a drug be with more than a The of and on a liver in a patient with DILI is with a more those who have or have liver from a patient with DILI the of injury, as was seen with the to and provides an to the a drug or HDS is the cause of liver injury by the laboratory, and clinical features and of more common causes of liver is to the data and a is from to of clinical have been developed for DILI and in the and to liver injury to to to to liver injury to to to to to to causes of liver injury to to to to or of to to to to to manifestations to of to to to DILI to from the are and are from and clinical diagnostic of those (i.e., or is by in risk was developed for drug and for Liver expert and data support data with more data data from be with to features from the (Table The as the for of was in provides a from to and the with by injury. The was in and a from to with the The to the medications and for There are the of is more with the and the The is in clinical practice because was to be to the The is a of the with the of and from to the was to be to the in is currently of because of the lack of available and The is currently available online. This a of to and as well as the in data The risk and an of competing causes to and diagnostic is and to the for by the have in DILI or clinical practice because of lack of liver expert The developed by the of DILI from to (Table of expert the to for drug and of including liver in to This been to be as as the expert is available in clinical of in DILI There are in DILI with the patients be drugs or HDS products the drugs for In addition, and lack of of HDS liver is for by the of and with to drugs and HDS to by expert the clinical features of a patient with of the of the causes of liver regarding the the of developed a of with drug and by or Furthermore, of causes of liver injury have been or the is for for or and are data to of risk as in the of the have been in the by the the for for the risk of and for all The provides more guidance in the of the drug is for use in patients with liver being available is this provide more and and data to be in of the the of DILI from seen in the United States and (Table or in with more than a Furthermore, the been in liver injury and and needs to be statements are and and the and of drug and drug or HDS an of the laboratory, and histological features and of competing causes of liver injury. The expert developed by the is in clinical practice and in the need for The and more diagnostic with the risk of and are of The is a more and than are drug is in clinical in HDS HDS are the on a more than of the of dietary supplements in the in a supplements products as well as of be and have been for by for HDS are products are the of in or of supplements are of from individual and products have been including liver of HDS use and liver injury American more than on herbal products in on HDS of all of liver injury in of products in the United States is are to is and need to to the based on The and provides the regulatory for and in the United The regulatory in as in a in the the of a on the a of with of the of injury to a dietary can be reported by and to the and the are by the for and the of a is regulatory actions can be the including of a from the in the in the diagnosis of liver injury are by to is well supplements are to or of and are on the and usually from the of usually to in with the for is the of in products for the of HDS as a of leading to of to a the of injury can be because of the of the the lack of and of liver injury from these over‐the‐counter supplements cause the injury to by patients and HDS and Many of the of from HDS have from products such as and dietary supplements are in is of and the such the with the be Furthermore, the supplements implicated in liver injury are The are being to the from are or as in (Table HDS products and implicated in or liver reported and or reported and or case of reported of to of The the of The of the is for is for liver injury. of liver injury to have been with the being those in injury analysis of in the to of the of as being and with a with This risk been with in individuals to a herbal to and have patients with HDS leading to liver are more to or to patients with drug This be to of the as the cause of liver injury or of HDS to statements HDS are with of in the United States and leading to the of and can cause can have clinical, laboratory, and histological in the and the a is the of an individual patient HDS been with to in and in and of idiosyncratic DILI and with idiosyncratic DILI with a drug of drugs have an In nearly of patients have injury, the with either an or injury (Table a diagnosis of idiosyncratic DILI is the be patients with liver injury need to be for and those with and be to a liver because of of drug patients with DILI to of patients with DILI with be risk of because of liver or have patients with and as well as are risk for In addition, have patients with liver are risk of in a of and have been to patients with DILI risk of clinical features are with a of such as the of and on liver for patients with idiosyncratic DILI for liver and for patients and be to and and a and for the for Liver available DILI is as in liver or the of or histological of injury DILI The of DILI in the was with and patients with a liver injury being of patients (i.e., of leading to can be and reported of DILI from and to or to of (Table of idiosyncratic patients with DILI is for all patients with including the use of and as with and or for and (Table of be in adult patients with in of in a randomized controlled in patients with randomized of patients with DILI a of with with a of in with for use in a dose of of are to patients with including the as drug with and In a of (i.e., with be of in patients with features on as well as for patients with DILI from and (Table of and DILI randomized controlled trials are to the dose and for patients with idiosyncratic DILI to per in if to in data patients to if with for duration in in with features per of for of for dose and duration can be in with by use with for from medications and patients or use to with for to a of to in and with liver liver drug with and of In to be for are data clinical with for with to In addition, be of for patients with because of and is a of from and use been with in patients with with statements and with idiosyncratic DILI with an liver injury or be of in In of patients with idiosyncratic DILI are risk for including liver and of of the of in idiosyncratic of of these individuals to a liver is liver injury is in of patients with DILI and be more in those with DILI. risk for patients with DILI with and and as well as those with and on liver and those with and liver of the drug with of and are the of idiosyncratic DILI of be of in adult patients with this is for for be of in patients with idiosyncratic including those with and features on liver the dose and duration are because of the lack of controlled clinical is an for patients with DILI is to is a is for use in and with to with the drug be the is for a or is as a over‐the‐counter In is to in 100,000 to and The of from the of with all idiosyncratic The reason for this is drugs with is a dose‐related with all to liver injury in to was to be a cause of in of or in the of or because of the lack of of the use of risk for and can to of as well as use of and medications can the and to of the data are in with these is by a of diagnosis of is based on a of of as a can to of liver injury with 1000 the of (Table of a a can the patients risk of liver of been as a more to in patients or with an this is and of of of use to per or of and can to in Liver injury of in to 1000 with in is and can to liver or and is in to 1000 with in such as can liver injury can to liver or to risk of available causes of liver injury clinical to exclude risk for and for dose if of in nor by as if of or by the those with of liver injury, is is and is of liver and in and to a liver of a of and and The of is to the of and can to because of of or is an as a dose by is of the liver be The of with The can be and a is a in the an by or and if more than is be of and of liver are and are nearly of patients either or a liver The patients a and have been developed and including the for Liver and the Liver Study In in the over‐the‐counter of been the of have the because of in with of patients statements is a to liver injury are a or is the leading cause of in the United diagnosis of on a of of an and of competing causes of liver injury. and be to all patients of a or can liver injury nearly if of is for patients The in is related to the of and of DILI in clinical practice The to liver injury from DILI is of the or individuals a drug with a to of DILI and clinical a validated a the to recommendations in the for a of In addition, patients medications are to or to are available and can be the have been and drug recommendations regarding of the for drug and of the for patients with liver in a The of currently drugs with or a for or if of liver injury or or for to the recommendations by medications have been with a a for drugs and have recommendations for the of to injury. In contrast, was clinical of a to or in patients with liver injury, a risk and been by the for the and clinical of all in clinical practice to is to individuals who are medications have a of for liver for the of in patients with liver of from to with and and and with drugs and can with because of and or of histological injury to DILI. can be seen with and a with of by are by the is in the of the with are by as to the of are in The development of these is to and are and are to be This of injury is reported with drugs such as and for medications In the United an individuals have individuals are for the of DILI to be than to be a leading cause of in the United States and (Table The for from to of to with a risk of including of with the for of and are available on individual patient the recommendations for have been with liver for all this been to be than for clinical of the are to individual and to liver is for those with liver use of liver or and or liver can be in those than of and to American are common in of and are with and liver patients are to and drugs and can be of a DILI to liver injury in of patients be for patients with can be with the development of and risk for liver injury with liver and liver is of all by and and liver been the to the and of the liver in more the need for liver patient The American of for the of and with the for and of The the use of in patients with to those with liver or by In contrast, the of for and and on in patients with risk for is and Liver is for those who have or those who have liver of dose liver are for all There are or drugs are on a by of patients with In are to and to dose or in to of on was of in to of patient was In the of patients with DILI to a an and injury as well as patients with randomized controlled trials have in the of and including in patients with liver In addition, have in patients with liver and the risk of and In the the of available liver be liver is liver in patients are or of be in patients with to can be on an individual risk are or in with are to more than of patients with The of and been to common for The of from in clinical trials and observational patients with injury in the of who in with and are risk of DILI is for of of liver injury in patients with and causes of liver for the the of and in of these Liver or and is patients have or for and with clinical and patients with liver injury with more is patients with an liver the be and per (Table patients with or or liver the be and a dose of per with for patients with be or can be for of the liver to be because of the risk of in of patients with and in those with can with a of liver statements of DILI is by patients to to with clinical and with drugs the and are to of DILI to the the of liver can be seen with drugs such as are because of and The and are a for drug and provide and recommendations for be including drug and for in to the common be for patient to of been to the of liver injury and can to of in and in of liver is as a to the of drugs to cause is to drugs cause DILI. liver are for all patients of liver is because of the risk of including patients with liver with liver and can and as use of in with be based on of risk and is the of for patients with a series of to the use based on the of liver injury. of need in DILI clinical the need for diagnostic and and and of the of DILI. of and DILI from is In addition, of the of DILI is to and and for DILI available of liver injury (i.e., are neither nor to nor are to clinical DILI in development liver injury the or of aim to the of liver and diagnostic including and as being more and for liver injury with from clinical in patients with (Table The and be more than in liver injury and be of of to and are to be in DILI In this a can be in the in as well as and as DILI have including the of in from the patient are with the drug (Table The a are the development of in from and liver is DILI and of is with use of case and in clinical trials and The and to DILI are well of in the of patients with DILI have are to of the of DILI with the of and for statements available of liver injury such as and are or to DILI. DILI to be by the lack of an to a drug as the DILI in development are currently being DILI diagnosis and as well as to provide DILI DILI use and for clinical and and to of DILI and